Qianru Hong
Biography
Overview
Qianru Hong is an associate in the firm's Mergers & Acquisitions practice group, based in Shanghai.
Qianru has participated in projects covering mergers and acquisitions, foreign direct investment, private equity and venture capital investments, capital markets, and other financing matters, investigations and compliance, intellectual property, employment, and general corporate matters, in industries spanning healthcare, internet, telecommunications, semiconductors, e-commerce finance, media and energy, among others.
Prior to joining White & Case, Qianru worked for an international firm's Shanghai office.
Experience
Representation of Western Digital Corporation (NASDAQ: WDC) in its US$624 million sale of 80% equity interest in SanDisk Semiconductor to JCET (SH: 600584).
Representation of Theorycraft Games Inc. in its publishing partnership with NetEase and Nexon for its new MOBA game.
Representation of a buyer consortium in the proposed going private transaction of 111, Inc. (NASDAQ:YI).
Representation of Acotec Scientific on its approximately US$520 million voluntary partial offer by Boston Scientific.
Representation of buyer consortium led by Fang Holdings (OTC: SFUNY) in a going private transaction involving China Index Holdings (NASDAQ: CIH) valued at approximately US$92 million.
Representation of Belite Bio, Inc (NASDAQ: BLTE) in its US$30 million follow-on offering.
Representation of Belite Bio, Inc (NASDAQ: BLTE) in its US$36 million IPO and listing on NASDAQRepresentation of OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds.
Representation of Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange.
Representation of BNP Paribas, China Construction Bank International, Industrial and Commercial Bank of China International and other underwriters in the spin-off and approximately US$126 million listing of Central China Management Company Limited on the Hong Kong Stock Exchange.
Representation of TTM Technologies, Inc. (NASDAQ: TTMI) in the sale of substantially all of its China-based mobility business to Chinese consortium AKM Meadville Electronics (Xiamen) Co., Ltd. for a combination of $550 million in cash and an estimated $110 million in retained accounts receivable.
Representation of a buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group (NASDAQ: CBMG), a biopharmaceutical company developing proprietary cell therapies for the treatment of cancer and degenerative diseases, in a "going private" transaction valued at approximately US$410 million.
Representation of a US listed company in its purchase of the China LED business of another US listed company for up to US$300 million.
Representation of JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange.
Representation of RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange.
Representation of a buyer consortium led by the management in a “going private” transaction of SORL Auto Parts, Inc. (NASDAQ: SORL) valued at approximately US$96 million.
Representation of the buyer group in going private transaction of China XD Plastics (NASDAQ: CXDC).
Representation of a biosimilar company with operations in China and Taiwan in its spin-off and follow-on financing.
Representation of a private equity fund in its US$756 million acquisition of three officer towers in China.
Representation of various venture capital deals including representations of internationally recognized venture capital funds and start-up or pre-IPO companies.
Representation of a U.S. public REIT in setting up an equity investment fund in Shanghai.
Representation of a U.S. coal technology company's financing and its foreign direct investment in China.
Representation of an Asian private equity fund in its acquisition of office buildings in China.
Representation of a biopharmaceutical company's spin-off and follow-up financing.
Representation of a Swedish security lock company in its acquisition of a well-known Chinese fingerprint lock company.
Representation of a U.S. floor manufacturer in its acquisition of its Chinese partners interest in their China joint venture.
Representation of small-loan companies in Chongqing in their loan transactions and with respect to PRC finance laws and regulations.
Representation of a leading high-tech company in its dismantling of its red-chip structure and its proposed IPO in China.
Representation of several matters representing multinational corporations establishing joint ventures, wholly foreign owned enterprises, representative offices and branch companies in China.
Representation of general corporate matters for a number of multinational companies' subsidiaries in China, including regulatory compliance and employment related advice.
